Has the U.K. Healthcare Sector valuation changed over the past few years?

Investors are pessimistic on the British Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 21.8x which is lower than its 3-year average PE of 28.1x. The industry is trading close to its 3-year average PS ratio of 3.3x.

Which industries have driven the changes within the U.K. Healthcare sector?

Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio. Analysts are expecting annual earnings growth of 28.4%, which is lower than the prior year's growth of 51.1% per year.

U.K. (FTSE) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 25 May 2026	UK£351.4b	UK£103.0b	UK£16.1b	26.7x	21.8x	3.4x
Wed, 22 Apr 2026	UK£370.1b	UK£101.5b	UK£16.0b	22.9x	23.1x	3.6x
Fri, 20 Mar 2026	UK£358.9b	UK£101.6b	UK£16.1b	21.2x	22.3x	3.5x
Sun, 15 Feb 2026	UK£389.0b	UK£100.4b	UK£15.7b	25.9x	24.8x	3.9x
Tue, 13 Jan 2026	UK£357.4b	UK£100.1b	UK£15.0b	23.4x	23.9x	3.6x
Thu, 11 Dec 2025	UK£343.1b	UK£100.6b	UK£15.0b	22.7x	22.8x	3.4x
Sat, 08 Nov 2025	UK£333.7b	UK£101.3b	UK£15.1b	24.4x	22.1x	3.3x
Mon, 06 Oct 2025	UK£324.0b	UK£98.3b	UK£12.0b	28.2x	26.9x	3.3x
Wed, 03 Sep 2025	UK£310.7b	UK£101.1b	UK£12.1b	28.8x	25.7x	3.1x
Fri, 01 Aug 2025	UK£299.8b	UK£101.9b	UK£11.7b	30x	25.6x	2.9x
Sun, 29 Jun 2025	UK£280.4b	UK£96.2b	UK£10.7b	32.3x	26.3x	2.9x
Tue, 27 May 2025	UK£286.9b	UK£96.8b	UK£10.7b	29.9x	26.7x	3x
Thu, 24 Apr 2025	UK£279.3b	UK£97.2b	UK£9.7b	28.7x	28.9x	2.9x
Sat, 22 Mar 2025	UK£307.1b	UK£98.5b	UK£9.7b	27.6x	31.8x	3.1x
Mon, 17 Feb 2025	UK£305.8b	UK£99.5b	UK£9.3b	29x	32.8x	3.1x
Wed, 15 Jan 2025	UK£247.3b	UK£87.5b	UK£7.8b	29.8x	31.6x	2.8x
Fri, 13 Dec 2024	UK£248.4b	UK£85.4b	UK£7.6b	30.5x	32.8x	2.9x
Sun, 10 Nov 2024	UK£238.6b	UK£83.0b	UK£7.4b	26.3x	32x	2.9x
Tue, 08 Oct 2024	UK£274.9b	UK£82.5b	UK£8.9b	29.1x	31x	3.3x
Thu, 05 Sep 2024	UK£302.1b	UK£82.1b	UK£8.8b	33.9x	34.2x	3.7x
Sat, 03 Aug 2024	UK£291.1b	UK£83.2b	UK£8.9b	33x	32.6x	3.5x
Mon, 01 Jul 2024	UK£283.4b	UK£82.0b	UK£9.4b	30.1x	30.1x	3.5x
Wed, 29 May 2024	UK£288.0b	UK£81.5b	UK£9.4b	31.4x	30.7x	3.5x
Fri, 26 Apr 2024	UK£283.7b	UK£82.1b	UK£9.9b	30.2x	28.5x	3.5x
Sun, 24 Mar 2024	UK£264.9b	UK£81.1b	UK£9.6b	34.4x	27.5x	3.3x
Tue, 20 Feb 2024	UK£261.1b	UK£79.8b	UK£9.4b	35.9x	27.7x	3.3x
Thu, 18 Jan 2024	UK£272.6b	UK£84.1b	UK£10.6b	39.1x	25.6x	3.2x
Sat, 16 Dec 2023	UK£261.7b	UK£84.1b	UK£10.7b	40.2x	24.6x	3.1x
Mon, 13 Nov 2023	UK£257.8b	UK£85.7b	UK£10.8b	40.8x	23.8x	3x
Wed, 11 Oct 2023	UK£279.5b	UK£85.6b	UK£10.3b	40.8x	27.1x	3.3x
Fri, 08 Sep 2023	UK£273.0b	UK£84.8b	UK£10.2b	40.2x	26.8x	3.2x
Sun, 06 Aug 2023	UK£274.3b	UK£83.9b	UK£10.1b	43.3x	27x	3.3x
Tue, 04 Jul 2023	UK£265.5b	UK£82.7b	UK£7.9b	42.7x	33.7x	3.2x
Thu, 01 Jun 2023	UK£283.8b	UK£83.8b	UK£8.0b	48.1x	35.5x	3.4x


GB Market	1.53%
Healthcare	1.59%
Life Sciences	6.48%
Healthcare Services	3.42%
Biotech	2.30%
Healthtech	2.10%
Pharma	1.64%
Medical Equipment	-0.22%

Company	Last Price	7D	1Y	Valuation
AZN AstraZeneca	UK£139.16	1.5% +UK£3.2b	33.3%	PE27.9x
GSK GSK	UK£19.15	2.1% +UK£1.5b	34.3%	PE13.1x
HLN Haleon	UK£3.44	2.0% +UK£593.6m	-16.5%	PE18.3x
SN. Smith & Nephew	UK£11.38	1.4% +UK£136.6m	7.1%	PE20.9x
ONT Oxford Nanopore Technologies	UK£1.29	7.8% +UK£91.4m	2.6%	PS5.6x

Announcement • May 23

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Daiichi Sankyo and AstraZeneca’s Datroway was approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval follows Priority Review by the U.S. Food and Drug Administration (FDA) based on results from the TROPION-Breast02 phase 3 trial which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. In the trial, Datroway demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival (OS) versus investigator’s choice of chemotherapy (hazard ratio [HR]=0.79; 95% confidence interval [CI]: 0.64-0.98; p=0.0290). Median OS was 23.7 months for patients treated with Datroway versus 18.7 months for those treated with chemotherapy. Datroway reduced the risk of disease progression or death by 43% compared to chemotherapy (HR=0.57; 95% CI: 0.47-0.69). This application was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, reviews are ongoing in Australia, Canada, Singapore and Switzerland. Additional reviews are underway in the EU, China and Japan. Based on the results of TROPION-Breast02, datopotamab deruxtecan-dlnk (Datroway) has been included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a Category 1 Preferred first-line treatment option for patients with metastatic TNBC who are not candidates for immunotherapy. Daiichi Sankyo and AstraZeneca are committed to ensuring that patients in the U.S. who are prescribed Datroway can access the medication and receive necessary financial support. Provider and patient support, reimbursement and distribution for Datroway in the U.S. will be accessible by visiting www.Datroway4U.com or calling 1-855-Datro4U (1-855-328-7648). Please visit www.Datroway.com for full Prescribing Information, including the Medication Guide. TROPION-Breast02 is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of Datroway versus investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin or eribulin) in patients with previously untreated locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. This included patients whose tumors did not express PD-L1 as well as patients with PD-L1 expressing tumors who could not receive immunotherapy due to prior exposure in early-stage disease, comorbidities or immunotherapy not being accessible in their geography. Enrollment included patients with de novo or recurrent disease, regardless of disease-free interval, and those with poor prognostic factors such as stable brain metastases. The dual primary endpoints of TROPION-Breast02 are PFS as assessed by BICR and OS. Secondary endpoints include PFS as assessed by investigator, ORR, duration of response, disease control rate, pharmacokinetics and safety. TROPION-Breast02 enrolled 644 patients at sites in Africa, Asia, Europe, North America and South America. Datroway (datopotamab deruxtecan; datopotamab deruxtecan-dlnk in the U.S. only) is a TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Datroway is one of seven DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datroway is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Datroway (6 mg/kg) is approved in more than 40 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HR positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease based on the results from the TROPION-Breast01 trial. Datroway (6 mg/kg) is approved in Brazil, Russia and the U.S. for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, based on the results from the TROPION-Breast02 trial. Datroway (6 mg/kg) is approved in Russia and the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy, based on the results from TROPION-Lung05 and TROPION-Lung01 trials. Continued approval for this indication in the U.S. may be contingent upon verification and description of clinical benefit in a confirmatory trial. A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of Datroway across multiple cancers, including NSCLC, TNBC and urothelial cancer. The program includes eight phase 3 trials in lung cancer, five phase 3 trials in breast cancer, and one phase 3 trial and one phase 2/3 trial in urothelial cancer evaluating Datroway as a monotherapy and in combination with other cancer treatments in various settings. DATROWAY (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

Announcement • May 06

Convatec Showcases and Launches Advanced Wound Care Products and Technologies

Convatec, a medical products and technology company focused on chronic condition management, took to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management with skin friendly adhesion for longer lasting wear time. ConvaNiox™: A solution, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings. Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds. ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta with the reproducibility and safety profile of a medical device. ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing. This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1,500,000,000 Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades. As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including: 6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing. The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers. 7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing. The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre. Title Lead presenter Session information (CEST) Aquacel® Ag+ Extra™ Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings Rebecca Rodger Wednesday 6 May 17:35 - 17:43 Room 4B Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial Rebecca Rodger Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 ConvaNiox™ Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens Tilly Coleborn Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model Tilly Coleborn Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds Dr. Francesca Pasquali Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study Dr. Marco Meloni Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form Natalia Maella-Rius Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 ConvaFoam™ Performance and user satisfaction with a superabsorbent dressing: results from an international survey Janet MacKenzie Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement Rebecca Rodger Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 ConvaMatrix™ The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real world data Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service Michele Rocha Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model Michele Rocha Thursday 7 May 16:30 - 16:35 E-Poster Screen 4.

U.K. (FTSE) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Innovent Biologics And HUTCHMED Jointly Announce NMPA Approval For TYVYT (Sintilimab Injection) In Combination With ELUNATE (Fruquintinib) For The Treatment Of Patients With Locally Advanced Or Metastatic Renal Cell Carcinoma

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Oxford Nanopore Technologies plc Announces Executive Appointments

H.B. Fuller Company (NYSE:FUL) proposed to acquire Advanced Medical Solutions Group plc (AIM:AMS).

GSK plc to Report Q3, 2026 Results on Oct 28, 2026

CVSG: Neutral Coverage And Buyback Pressure Will Shape Future Earnings Profile

Full year 2025 earnings released: UK£0.093 loss per share (vs UK£0.085 loss in FY 2024)

GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside

Consensus EPS estimates increase by 42%

New minor risk - Share price stability

SN.: Buybacks And New Medical Offerings Will Support Future Upside Potential

HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating

Convatec Showcases and Launches Advanced Wound Care Products and Technologies

New major risk - Shareholder dilution

First half 2026 earnings released: UK£0.004 loss per share (vs UK£0.002 loss in 1H 2025)

Tristel's US Expansion Could Spark a 286% Revenue Surge